Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

Current Opinion in Pharmacology

Volumn 8, Issue 4, 2008, Pages 393-412

  Yap, Timothy A ^a,b   Garrett, Michelle D ^a   Walton, Mike I ^a   Raynaud, Florence ^a   de Bono, Johann S ^a,b   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AP 23573; BIOLOGICAL MARKER; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GDC 0941; IC 877114; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RAPAMYCIN; RITUXIMAB; SF 1126; TEMOZOLOMIDE; TEMSIROLIMUS; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 765;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EPIGENETICS; GENE AMPLIFICATION; GENE MUTATION; GENE SILENCING; HUMAN; HYPOTENSION; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MUCOCUTANEOUS TOXICITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 51449095342     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.08.004     Document Type: Review

References (185)

1. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
2. Bellacosa A., Kumar C.C., Di Cristofano A., and Testa J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94 (2005) 29-86
3. Manning B.D., and Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 129 (2007) 1261-1274
4. Engelman J.A., Luo J., and Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7 (2006) 606-619
5. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 (2005) 988-1004
6. Tokunaga E., Kimura Y., Oki E., Ueda N., Futatsugi M., Mashino K., Yamamoto M., Ikebe M., Kakeji Y., Baba H., et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118 (2006) 284-289
7. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
8. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., Waterfield M.D., and Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 (1994) 527-532
9. Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., and Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64 (2004) 5048-5050
10. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., and Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64 (2004) 7678-7681
11. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
12. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 (1999) 99-102
13. Crabbe T., Welham M.J., and Ward S.G. The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem Sci 32 (2007) 450-456
14. Kang S., Bader A.G., and Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102 (2005) 802-807
15. Vogt P.K., Kang S., Elsliger M.A., and Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32 (2007) 342-349
16. Sarker D., and Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96 (2007) 213-268
17. Trotman L.C., and Pandolfi P.P. PTEN and p53: who will get the upper hand?. Cancer Cell 3 (2003) 97-99
18. Salmena L., Carracedo A., and Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 133 (2008) 403-414
19. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 (2004) 193-204
20. Soung Y.H., Lee J.W., Nam S.W., Lee J.Y., Yoo N.J., and Lee S.H. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 70 (2006) 285-289
21. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297 (2002) 63-64
22. Weinstein I.B., and Joe A.K. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3 (2006) 448-457
23. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., and Maehara Y. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8 (2008) 27-36
24. Workman P., Clarke P.A., Guillard S., and Raynaud F.I. Drugging the PI3 kinome. Nat Biotechnol 24 (2006) 794-796
25. Lopiccolo J., Blumenthal G.M., Bernstein W.B., and Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11 (2008) 32-50
26. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., and Nicosia S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 (2005) 7482-7492
27. Foukas L.C., Claret M., Pearce W., Okkenhaug K., Meek S., Peskett E., Sancho S., Smith A.J., Withers D.J., and Vanhaesebroeck B. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 (2006) 366-370. Generation of mice carrying a knock-in mutation in p110α revealed a crucial role of this PI3K isoform in somatic growth and insulin signaling.
28. ••], this paper also demonstrated pharmacologically the importance of p110α in insulin signaling.
29. Vogt P.K., Bader A.G., and Kang S. PI 3-kinases: hidden potentials revealed. Cell Cycle 5 (2006) 946-949
30. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269 (1994) 5241-5248
31. Garlich J.R., De P., Dey N., Su J.D., Peng X., Miller A., Murali R., Lu Y., Mills G.B., Kundra V., et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68 (2008) 206-215
32. Nutley B., Raynaud F., Hayes A., Goddard P., Jarman M., and Workman P. Pharmacokinetics and metabolism of the phospatidylinositol 3-kinase inhibitor LY294002 in the mouse [abstract #2044]. Proceedings of the American Association of Cancer Research 92nd Annual Meeting 2001, vol 92 (2001) 380
33. Schwertschlag U., Chiorean E., Anthony S., Sweeney C., Borad M., Von Hoff D., Garlich J., Shelton C., and Ramanathan R. Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors. J Clin Oncol 26 (2008) [May 20 suppl; abstr 14532]
34. Yu K., Lucas J., Zhu T., Zask A., Gaydos C., Toral-Barza L., Gu J., Li F., Chaudhary I., Cai P., et al. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4 (2005) 538-545
35. Zhu T., Gu J., Yu K., Lucas J., Cai P., Tsao R., Gong Y., Li F., Chaudhary I., Desai P., et al. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J Med Chem 49 (2006) 1373-1378
36. Ihle N.T., Paine-Murrieta G., Berggren M.I., Baker A., Tate W.R., Wipf P., Abraham R.T., Kirkpatrick D.L., and Powis G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4 (2005) 1349-1357
37. Howes A.L., Chiang G.G., Lang E.S., Ho C.B., Powis G., Vuori K., and Abraham R.T. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 6 (2007) 2505-2514
38. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., Minion D.J., Halter R.J., Wipf P., Abraham R., et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3 (2004) 763-772
39. Sadhu C., Masinovsky B., Dick K., Sowell C.G., and Staunton D.E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 170 (2003) 2647-2654
40. Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Fine R., Weis S., Hood J., Demaria A., Soll R., and Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A 103 (2006) 19866-19871
41. Yaguchi S., Fukui Y., Koshimizu I., Yoshimi H., Matsuno T., Gouda H., Hirono S., Yamazaki K., and Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98 (2006) 545-556. An early nanomolar pan-Class I isoform-selective inhibitor, lacking activity on mTOR, which shows activity in animal models of cancer.
42. Kong D., and Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 98 (2007) 1638-1642
43. Shapiro G., Edelman G., Calvo E., Aggarwal S., and Laird A. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor [abstract C205]. 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2007)
44. Foster P. Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147 [Abstract B251]. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2007)
45. Friedman L., Genentech I., and South San Francisco C.A. GDC-0941, a potent, selective, orally bioavailable inhibitor of class I PI3K [abstract LB-110]. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. April 12-16, 2008 (2008), AACR, San Diego, CA/Philadelphia, PA
46. Folkes A., Baker S., Chuckowree I., Eccles S., Hayes A., Hancox T., Latif M., Olivero A., Patel S., Pergl-Wilson G., et al. The discovery of GDC-0941: a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. April 12-16, 2008 (2008), AACR, San Diego, CA/Philadelphia, PA
47. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349. Reports the activity of PI-103 against glioma cells and links this to inhibition of PI3Kα and mTOR.
48. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Yamano M., Okada M., Ohta M., Tsukamoto S., Raynaud F.I., et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett 17 (2007) 2438-2442. One of a series of four papers from this group of collaborators reporting the discovery and structure-activity relationships for the pyridofuropyrimidine series from which PI-103 emerged.
49. Raynaud F.I., Eccles S., Clarke P.A., Hayes A., Nutley B., Alix S., Henley A., Di-Stefano F., Ahmad Z., Guillard S., et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67 (2007) 5840-5850. Reports the detailed properties and antitumor activity in animal models of the pyridofuropyrimidine pan-Class I selective PI3K inhibitor PI-103.
50. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 (2007) 297-315
51. Raynaud F., Hayes H., Di Stefano F., Clarke P., Valenti M., Ahmad Z., Eccles S., Folkes A., Saghir N., Robson A., et al. Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. April 12-16, 2008 (2008), AACR, San Diego, CA/Philadelphia, PA
52. Laird D. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR [Abstract B250]. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications (2007)
53. Papadopoulos K., Markman B., Tabernero J., Patnaik A., Heath E., DeCillis A., Laird D., Aggarwal S., Nguyen L., and LoRusso P. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 26 (2008) [May 20 suppl; abstr 3510]
54. Stauffer F., Maira S.M., Furet P., and Garcia-Echeverria C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg Med Chem Lett 18 (2008) 1027-1030
55. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7 (2008) 1851-1863. A new PI3 kinase inhibitor in the clinic.
56. Sellars W.R. Targeting the PI3K/mTOR pathway in cancer. Pezcoller Foundation J 30 (2008) 13-14
57. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 84 (1987) 5034-5037
58. Coffer P.J., and Woodgett J.R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 201 (1991) 475-481
59. Jones P.F., Jakubowicz T., and Hemmings B.A. Molecular cloning of a second form of rac protein kinase. Cell Regul 2 (1991) 1001-1009
60. Murthy S.S., Tosolini A., Taguchi T., and Testa J.R. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet 88 (2000) 38-40
61. Koseoglu S., Lu Z., Kumar C., Kirschmeier P., and Zou J. AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biol Ther 6 (2007) 755-762
62. Yang Z.Z., Tschopp O., Baudry A., Dummler B., Hynx D., and Hemmings B.A. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 32 (2004) 350-354
63. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15 (2005) 761-764
64. Litman P., Ohne O., Ben-Yaakov S., Shemesh-Darvish L., Yechezkel T., Salitra Y., Rubnov S., Cohen I., Senderowitz H., Kidron D., et al. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry 46 (2007) 4716-4724
65. Castillo S.S., Brognard J., Petukhov P.A., Zhang C., Tsurutani J., Granville C.A., Li M., Jung M., West K.A., Gills J.G., et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 64 (2004) 2782-2792
66. Luo Y., Smith R.A., Guan R., Liu X., Klinghofer V., Shen J., Hutchins C., Richardson P., Holzman T., Rosenberg S.H., et al. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 43 (2004) 1254-1263
67. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., de Jong R., Han E.K., Li T., Stoll V.S., Powlas J.A., et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4 (2005) 977-986
68. Lin X., Murray J.M., Rico A.C., Wang M.X., Chu D.T., Zhou Y., Del Rosario M., Kaufman S., Ma S., Fang E., et al. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg Med Chem Lett 16 (2006) 4163-4168
69. Li Q., Li T., Zhu G.D., Gong J., Claibone A., Dalton C., Luo Y., Johnson E.F., Shi Y., Liu X., et al. Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: synthesis and biological evaluation. Bioorg Med Chem Lett 16 (2006) 1679-1685
70. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64 (2004) 4394-4399
71. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., and Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2 (2003) 1093-1103
72. Hilgard P., Klenner T., Stekar J., Nossner G., Kutscher B., and Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33 (1997) 442-446
73. Hideshima T., Catley L., Yasui H., Ishitsuka K., Raje N., Mitsiades C., Podar K., Munshi N.C., Chauhan D., Richardson P.G., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 (2006) 4053-4062
74. Momota H., Nerio E., and Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65 (2005) 7429-7435
75. Nyakern M., Cappellini A., Mantovani I., and Martelli A.M. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 5 (2006) 1559-1570
76. Argiris A., Cohen E., Karrison T., Esparaz B., Mauer A., Ansari R., Wong S., Lu Y., Pins M., Dancey J., et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 5 (2006) 766-770
77. Bailey H.H., Mahoney M.R., Ettinger D.S., Maples W.J., Fracasso P.M., Traynor A.M., Erlichman C., and Okuno S.H. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 107 (2006) 2462-2467
78. Ernst D.S., Eisenhauer E., Wainman N., Davis M., Lohmann R., Baetz T., Belanger K., and Smylie M. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23 (2005) 569-575
79. Knowling M., Blackstein M., Tozer R., Bramwell V., Dancey J., Dore N., Matthews S., and Eisenhauer E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 24 (2006) 435-439
80. Leighl N.B., Dent S., Clemons M., Vandenberg T.A., Tozer R., Warr D.G., Crump R.M., Hedley D., Pond G.R., Dancey J.E., et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 108 (2008) 87-92
81. Marsh Rde W., Rocha Lima C.M., Levy D.E., Mitchell E.P., Rowland Jr. K.M., and Benson III A.B. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 30 (2007) 26-31
82. Posadas E.M., Gulley J., Arlen P.M., Trout A., Parnes H.L., Wright J., Lee M.J., Chung E.J., Trepel J.B., Sparreboom A., et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4 (2005) 1133-1137
83. Birch R., Chawla S., Nemunaitis J., Savage P., Kaiser P., Spira A., Cervera A., Middleman E., Sausville E., Knowling M., et al. Perifosine (P) as an active agent in the treatment of patients with advanced sarcoma. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (June 20 Supplement) (2007) 10059
84. Richardson P., Lonial S., Jakubowiak A., Krishnan A., Wolf J., Densmore J., Singhal S., Ghobrial I., Stephenson J., Mehta J., et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. ASH Annual Meeting Abstract 108 (2006)
85. Ghobrial I., Leleu X., Rubin N., Leduc R., Chuma S., Nelson M., Sportelli P., Richardson P., Treon S., and Anderson K. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol 26 (2008) [May 20 suppl; abstr 8546]
86. Ebrahimi B., Nemunaitis J., Shiffman R., Birch R., Diaz-Lacayo M., Berdeaux D., Rettenmaier M., Goggins T., Henderson I., and Group OCO. A phase 1 study of daily oral perifosine (P) with weekly paclitaxel (T). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (June 20 Supplement) (2006) 13117
87. Vink S.R., Schellens J.H., Beijnen J.H., Sindermann H., Engel J., Dubbelman R., Moppi G., Hillebrand M.J., Bartelink H., and Verheij M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 80 (2006) 207-213
88. Cervera A., Bernhardt B., Nemunaitis J., Ebrahimi B., Birch R., Richards D., Smith G., Allerton J., Henderson I., and Group OCO. Perifosine (P) can be combined with docetaxel (T) without dose reduction of either drug. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (June 20 Supplement) (2006) 13066
89. Goggins T., Nemunaitis J., Shiffman R., Birch R., Berdeaux D., Rettenmaier M., Diaz-Lacayo M., Henderson I., and Group OCO. A phase 1 study of daily oral perifosine (P) with every 3-week paclitaxel (T). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (June 20 Supplement) (2006) 13134
90. Weiss S., Nemunaitis J., Diaz-Lacayo M., Birch R., Ebrahimi B., Berdeaux D., Allerton J., Gardner L., Henderson I., and Group OCO. A phase 1 study of daily oral perifosine (P) and weekly gemcitabine (G). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (June 20 Supplement) (2006) 13084
91. Allerton J., Ebrahimi B., Schreeder M., Kaiser P., Chawla S., Sportelli P., Gardner L., Birch R., and Henderson I. Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC). J Clin Oncol 26 (2008) [May 20 suppl; abstr 14565]
92. Schreeder M., Figlin R., Stephenson J., Campos L., Chawla S., Spigel D., Spira A., Sportelli P., Gardner L., Birch R., et al. Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. J Clin Oncol 26 (2008) [May 20 suppl; abstr 16024]
93. Meuillet E.J., Ihle N., Baker A.F., Gard J.M., Stamper C., Williams R., Coon A., Mahadevan D., George B.L., Kirkpatrick L., et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 14 (2004) 513-527
94. Feun L.G., Blessing J.A., Barrett R.J., and Hanjani P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol 16 (1993) 506-508
95. Feun L.G., Savaraj N., Bodey G.P., Lu K., Yap B.S., Ajani J.A., Burgess M.A., Benjamin R.S., McKelvey E., and Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 44 (1984) 3608-3612
96. Schweinsberg P.D., Smith R.G., and Loo T.L. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem Pharmacol 30 (1981) 2521-2526
97. Rhodes N., Heerding D.A., Duckett D.R., Eberwein D.J., Knick V.B., Lansing T.J., McConnell R.T., Gilmer T.M., Zhang S.Y., Robell K., et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68 (2008) 2366-2374. A new AKT inhibitor in the clinic.
98. LoRusso P., Hurwitz H., Chiorean E., Jewell R., Lampkin T., Bachman K., Kumar R., Lebowitz P., and Weber B. AKT inhibitor GSK690693: preliminary results from the first time in human study. 2008 AACR Annual Meeting LB-68 (2008)
99. Lyons J., Grimshaw K., Woodhead S., Feltell R., Reule M., Smyth T., Seavers L., Harada I., Higgins J., Smith D., et al. AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation [Abstract B251]. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2007)
100. Breitenlechner C.B., Friebe W.G., Brunet E., Werner G., Graul K., Thomas U., Kunkele K.P., Schafer W., Gassel M., Bossemeyer D., et al. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J Med Chem 48 (2005) 163-170
101. Collins I., Caldwell J., Fonseca T., Donald A., Bavetsias V., Hunter L.J., Garrett M.D., Rowlands M.G., Aherne G.W., Davies T.G., et al. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg Med Chem 14 (2006) 1255-1273
102. Donald A., McHardy T., Rowlands M.G., Hunter L.J., Davies T.G., Berdini V., Boyle R.G., Aherne G.W., Garrett M.D., and Collins I. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J Med Chem 50 (2007) 2289-2292
103. Caldwell J.J., Davies T.G., Donald A., McHardy T., Rowlands M.G., Aherne G.W., Hunter L.K., Taylor K., Ruddle R., Raynaud F.I., et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem 51 (2008) 2147-2157. An example illustrating the utility of fragment screening and structure-based design.
104. Davies T.G., Verdonk M.L., Graham B., Saalau-Bethell S., Hamlett C.C., McHardy T., Collins I., Garrett M.D., Workman P., Woodhead S.J., et al. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol 367 (2007) 882-894. Paper reporting the generation of phosphorylated, AKT-inhibitor crystal structures, which represents an important step forward in the development of ATP-competitive AKT inhibitors.
105. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A.M., Leander K., Lee L.L., et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385 (2005) 399-408
106. DeFeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., McAvoy E., Robinson R.G., Duggan M.E., Lindsley C.W., et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4 (2005) 271-279
107. Bilodeau M.T., Balitza A.E., Hoffman J.M., Manley P.J., Barnett S.F., Defeo-Jones D., Haskell K., Jones R.E., Leander K., Robinson R.G., et al. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett 18 (2008) 3178-3182
108. Harding M.W. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 9 (2003) 2882-2886
109. Wu C., Wangpaichitr M., Feun L., Kuo M.T., Robles C., Lampidis T., and Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4 (2005) 25
110. deGraffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., Roth R.A., and Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10 (2004) 8059-8067
111. Dudkin L., Dilling M.B., Cheshire P.J., Harwood F.C., Hollingshead M., Arbuck S.G., Travis R., Sausville E.A., and Houghton P.J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7 (2001) 1758-1764
112. Korecka M., Solari S.G., and Shaw L.M. Sensitive, high throughput HPLC-MS/MS method with on-line sample clean-up for everolimus measurement. Ther Drug Monit 28 (2006) 484-490
113. Shi Y., Frankel A., Radvanyi L.G., Penn L.Z., Miller R.G., and Mills G.B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55 (1995) 1982-1988
114. Ito D., Fujimoto K., Mori T., Kami K., Koizumi M., Toyoda E., Kawaguchi Y., and Doi R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 118 (2006) 2337-2343
115. Dancey J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5 (2006) 1065-1073
116. Ratain M.J., Napoli K.L., Knightley Moshier K., Jiang X., Fleming G.F., Gajewski T.F., Jacobsen E., and Cohen E.E. A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies. 2007 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 25 18S (June 20 Supplement) (2007) 3510
117. Cohen E.E. mTOR: the mammalian target of replication. J Clin Oncol 26 (2008) 348-349
118. Chawla S., Tolcher A., Staddon A., Schuetze S., D'Amato G., Blay J., Loewy J., Kan R., and Demetri G. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (June 20 Supplement) (2007) 10076
119. Mita M.M., Mita A.C., Chu Q.S., Rowinsky E.K., Fetterly G.J., Goldston M., Patnaik A., Mathews L., Ricart A.D., Mays T., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26 (2008) 361-367
120. Hess G., Romaguera J., Verhoef G., Herbrecht R., Crump M., Strahs A., Clancy J., Hewes B., and Coiffier B. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J Clin Oncol 26 (2008) [May 20 suppl; abstr 8513]
121. Rizzieri D.A., Feldman E., Dipersio J.F., Gabrail N., Stock W., Strair R., Rivera V.M., Albitar M., Bedrosian C.L., and Giles F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14 (2008) 2756-2762
122. Chang S.M., Wen P., Cloughesy T., Greenberg H., Schiff D., Conrad C., Fink K., Robins H.I., De Angelis L., Raizer J., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
123. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., Peralba J.M., Jenkins R.B., Dakhil S.R., Morton R.F., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005) 5294-5304
124. Omuro A.M., Faivre S., and Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6 (2007) 1909-1919
125. Colombo N., McMeekin S., Schwartz P., Kostka J., Sessa C., Gehrig P., Holloway R., Braly P., Matei D., and Einstein M. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (June 20 Supplement) (2007) 5516
126. Mita M., Britten C., Poplin E., Tap W., Carmona A., Yonemoto L., Wages D., Bedrosian C., Rubin E., and Tolcher A. Deforolimus trial 106 - a phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J Clin Oncol 26 (2008) [May 20 suppl; abstr 3509]
127. Slomovitz B., Lu K., Johnston T., Munsell M., Ramondetta L., Broaddus R., Coleman R., Walker C., Gershenson D., Burke T., et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J Clin Oncol 26 (2008) [May 20 suppl; abstr 5502]
128. Duran I., Kortmansky J., Singh D., Hirte H., Kocha W., Goss G., Le L., Oza A., Nicklee T., Ho J., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95 (2006) 1148-1154
129. Rini B.I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14 (2008) 1286-1290
130. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281. Phase III clinical trial that demonstrated a significant improvement in overall survival in poor prognosis advanced renal-cell carcinoma patients treated with temsirolimus and which led to FDA approval.
131. Chan S., Scheulen M.E., Johnston S., Mross K., Cardoso F., Dittrich C., Eiermann W., Hess D., Morant R., Semiglazov V., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23 (2005) 5314-5322
132. Baselga J., van Dam P., Greil R., Gardner H., Bandaru R., Molloy B., Steinseifer J., Phillips P., Dixon J., and Rugo H. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. J Clin Oncol 26 (2008) [May 20 suppl; abstr 530]
133. Bhaskar P.T., and Hay N. The two TORCs and Akt. Dev Cell 12 (2007) 487-502
134. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
135. Di Cosimo S., Scaltriti M., Val D., Rojo F., Guzman M., Jimenez J., Seoane J., Arribas J., and Baselga J. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (June 20 Supplement) (2008) 3511
136. Yu K., Toral-Barza L., Shi C., Zhang W.G., and Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7 (2008) 307-315
137. Patnaik A., Ricart A., Cooper J., Papadopoulos K., Beeram M., Mita C., Mita M., Hufnagel D., Izbicka E., Tolcher A., et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (June 20 Supplement) (2008) 3512
138. Biomarkers Definitions Working Group, and Bethesda M. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
139. Thomas G.V. mTOR and cancer: reason for dancing at the crossroads?. Curr Opin Genet Dev 16 (2006) 78-84
140. Saal L.H., Johansson P., Holm K., Gruvberger-Saal S.K., She Q.B., Maurer M., Koujak S., Ferrando A.A., Malmstrom P., Memeo L., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104 (2007) 7564-7569
141. Choe G., Horvath S., Cloughesy T.F., Crosby K., Seligson D., Palotie A., Inge L., Smith B.L., Sawyers C.L., and Mischel P.S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
142. Thomas G.V., Horvath S., Smith B.L., Crosby K., Lebel L.A., Schrage M., Said J., De Kernion J., Reiter R.E., and Sawyers C.L. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 10 (2004) 8351-8356
143. Saxinger C., Conrads T.P., Goldstein D.J., and Veenstra T.D. Fully automated synthesis of (phospho)peptide arrays in microtiter plate wells provides efficient access to protein tyrosine kinase characterization. BMC Immunol 6 (2005) 1
144. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2 (2003) 131-138
145. Workman P. How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9 (2003) 891-902
146. Collins I., and Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2 (2006) 689-700
147. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441 (2006) 518-522
148. Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J., Frech M., Cron P., Cohen P., Lucocq J.M., and Hemmings B.A. Role of translocation in the activation and function of protein kinase B. J Biol Chem 272 (1997) 31515-31524
149. Frech M., Andjelkovic M., Ingley E., Reddy K.K., Falck J.R., and Hemmings B.A. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 272 (1997) 8474-8481
150. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 (1998) 13375-13378
151. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., and Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 95 (1998) 13513-13518
152. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
153. Bertelsen B.I., Steine S.J., Sandvei R., Molven A., and Laerum O.D. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 118 (2006) 1877-1883
154. Phillips W.A., Russell S.E., Ciavarella M.L., Choong D.Y., Montgomery K.G., Smith K., Pearson R.B., Thomas R.J., and Campbell I.G. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer 118 (2006) 2644-2646
155. Gallia G.L., Rand V., Siu I.M., Eberhart C.G., James C.D., Marie S.K., Oba-Shinjo S.M., Carlotti C.G., Caballero O.L., Simpson A.J., et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4 (2006) 709-714
156. Oda K., Stokoe D., Taketani Y., and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65 (2005) 10669-10673
157. Ollikainen M., Gylling A., Puputti M., Nupponen N.N., Abdel-Rahman W.M., Butzow R., and Peltomaki P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121 (2007) 915-920
158. Byun D.S., Cho K., Ryu B.K., Lee M.G., Park J.I., Chae K.S., Kim H.J., and Chi S.G. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 104 (2003) 318-327
159. Pedrero J.M., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., and Gonzalez M.V. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114 (2005) 242-248
160. Willner J., Wurz K., Allison K.H., Galic V., Garcia R.L., Goff B.A., and Swisher E.M. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38 (2007) 607-613
161. Wu G., Xing M., Mambo E., Huang X., Liu J., Guo Z., Chatterjee A., Goldenberg D., Gollin S.M., Sukumar S., et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7 (2005) R609-R616
162. Mizoguchi M., Nutt C.L., Mohapatra G., and Louis D.N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 14 (2004) 372-377
163. Philp A.J., Campbell I.G., Leet C., Vincan E., Rockman S.P., Whitehead R.H., Thomas R.J., and Phillips W.A. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61 (2001) 7426-7429
164. Halachmi N., Halachmi S., Evron E., Cairns P., Okami K., Saji M., Westra W.H., Zeiger M.A., Jen J., and Sidransky D. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23 (1998) 239-243
165. Kohno T., Takahashi M., Manda R., and Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22 (1998) 152-156
166. Birck A., Ahrenkiel V., Zeuthen J., Hou-Jensen K., and Guldberg P. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 114 (2000) 277-280
167. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., and Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57 (1997) 3660-3663
168. Harima Y., Sawada S., Nagata K., Sougawa M., Ostapenko V., and Ohnishi T. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol 18 (2001) 493-497
169. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15 (1997) 356-362
170. Kawamura N., Nagai H., Bando K., Koyama M., Matsumoto S., Tajiri T., Onda M., Fujimoto J., Ueki T., Konishi N., et al. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 90 (1999) 413-418
171. Dahia P.L., Marsh D.J., Zheng Z., Zedenius J., Komminoth P., Frisk T., Wallin G., Parsons R., Longy M., Larsson C., et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57 (1997) 4710-4713
172. Hsieh M.C., Lin S.F., Shin S.J., Liu T.C., Chang J.G., and Lee J.P. Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors. Kaohsiung J Med Sci 16 (2000) 9-12
173. Nakahara Y., Nagai H., Kinoshita T., Uchida T., Hatano S., Murate T., and Saito H. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 12 (1998) 1277-1280
174. Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., and Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 92 (1998) 3410-3415
175. Knobbe C.B., and Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13 (2003) 507-518
176. Actor B., Cobbers J.M., Buschges R., Wolter M., Knobbe C.B., Lichter P., Reifenberger G., and Weber R.G. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 34 (2002) 416-427
177. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 93 (1996) 3636-3641
178. Nakayama K., Nakayama N., Kurman R.J., Cope L., Pohl G., Samuels Y., Velculescu V.E., Wang T.L., and Shih Ie M. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5 (2006) 779-785
179. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64 (1995) 280-285
180. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
181. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., and Roth R.A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274 (1999) 21528-21532
182. Hollestelle A., Elstrodt F., Nagel J.H., Kallemeijn W.W., and Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5 (2007) 195-201
183. van Dam P.A., Vergote I.B., Lowe D.G., Watson J.V., van Damme P., van der Auwera J.C., and Shepherd J.H. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47 (1994) 914-919
184. Douglas D.A., Zhong H., Ro J.Y., Oddoux C., Berger A.D., Pincus M.R., Satagopan J.M., Gerald W.L., Scher H.I., Lee P., et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 11 (2006) 2518-2525
185. Livasy C.A., Reading F.C., Moore D.T., Boggess J.F., and Lininger R.A. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100 (2006) 101-106